Litcius/Paper detail

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Grégoire Marret, Nicolás Isambert, Keyvan Rezaï, Jocelyn Gal, Esma Saâda-Bouzid, Frédéric Rolland, Maggy Chausson, Édith Borcoman, Marie Alt, Jerzy Klijanienko, Damien Vansteene, J. Guigay, Maud Kamal, Ivan Bièche, Christophe Le Tourneau, UNICANCER Head, Neck Group

2021Investigational New Drugs25 citationsDOI

Topics & Concepts

CetuximabMedicineHead and neck squamous-cell carcinomaInternal medicinePhases of clinical researchOncologyToxicityResponse Evaluation Criteria in Solid TumorsHead and neck cancerGastroenterologyCancerColorectal cancerPI3K/AKT/mTOR signaling in cancerProtein Degradation and InhibitorsLung Cancer Treatments and Mutations
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma | Litcius